Does the media favor ABUS or ABCL?

In the previous week, Arbutus Biopharma had 9 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for Arbutus Biopharma and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.15 beat Arbutus Biopharma's score of 0.83 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive AbCellera Biologics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GMTX or ABUS?

Arbutus Biopharma has a consensus target price of $5.00, indicating a potential downside of 4.12%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Arbutus Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer GMTX or ABUS?

In the previous week, Arbutus Biopharma had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 13 mentions for Arbutus Biopharma and 1 mentions for Gemini Therapeutics. Arbutus Biopharma's average media sentiment score of 0.83 beat Gemini Therapeutics' score of 0.75 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is QURE or ABUS more profitable?

Arbutus Biopharma has a net margin of 84.22% compared to uniQure's net margin of -1,350.73%. Arbutus Biopharma's return on equity of 90.98% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Arbutus Biopharma 84.22% 90.98% 82.34%

Does the media refer more to QURE or ABUS?

In the previous week, Arbutus Biopharma had 11 more articles in the media than uniQure. MarketBeat recorded 13 mentions for Arbutus Biopharma and 2 mentions for uniQure. uniQure's average media sentiment score of 1.54 beat Arbutus Biopharma's score of 0.83 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Arbutus Biopharma 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, VCYT or ABUS?

Veracyte has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 6.80 $66.35M $1.41 31.04 Arbutus Biopharma $14.08M 73.28 -$33.50M $0.79 6.60

Does the media refer more to VCYT or ABUS?

In the previous week, Arbutus Biopharma had 2 more articles in the media than Veracyte. MarketBeat recorded 13 mentions for Arbutus Biopharma and 11 mentions for Veracyte. Veracyte's average media sentiment score of 1.40 beat Arbutus Biopharma's score of 0.83 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor CLDX or ABUS?

In the previous week, Arbutus Biopharma had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Arbutus Biopharma and 3 mentions for Celldex Therapeutics. Arbutus Biopharma's average media sentiment score of 0.83 beat Celldex Therapeutics' score of 0.67 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Arbutus Biopharma (ABUS) Competitors

$5.22 +0.02 (+0.29%)

As of 03:45 PM Eastern

Compare

ABUS vs. ABCL, GMTX, QURE, VCYT, and CLDX

Should you buy Arbutus Biopharma stock or one of its competitors? Arbutus Biopharma's main competitors and comparable companies include AbCellera Biologics (ABCL), Gemini Therapeutics (GMTX), uniQure (QURE), Veracyte (VCYT), and Celldex Therapeutics (CLDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arbutus Biopharma compare to AbCellera Biologics?

Arbutus Biopharma (NASDAQ:ABUS) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Arbutus Biopharma has a net margin of 84.22% compared to AbCellera Biologics' net margin of -248.83%. Arbutus Biopharma's return on equity of 90.98% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Arbutus Biopharma currently has a consensus price target of $5.00, suggesting a potential downside of 4.12%. AbCellera Biologics has a consensus price target of $12.83, suggesting a potential upside of 4.21%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arbutus Biopharma has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	73.28	-$33.50M	$0.79	6.60
AbCellera Biologics	$75.13M	50.26	-$146.41M	-$0.54	N/A

In the previous week, Arbutus Biopharma had 9 more articles in the media than AbCellera Biologics. MarketBeat recorded 13 mentions for Arbutus Biopharma and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.15 beat Arbutus Biopharma's score of 0.83 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
AbCellera Biologics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

AbCellera Biologics beats Arbutus Biopharma on 9 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Arbutus Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Arbutus Biopharma	$14.08M	73.28	-$33.50M	$0.79	6.60

Arbutus Biopharma has a net margin of 84.22% compared to Gemini Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Arbutus Biopharma	84.22%	90.98%	82.34%

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Arbutus Biopharma had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 13 mentions for Arbutus Biopharma and 1 mentions for Gemini Therapeutics. Arbutus Biopharma's average media sentiment score of 0.83 beat Gemini Therapeutics' score of 0.75 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gemini Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Arbutus Biopharma has a consensus target price of $5.00, indicating a potential downside of 4.12%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Arbutus Biopharma beats Gemini Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to uniQure?

uniQure (NASDAQ:QURE) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Arbutus Biopharma has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	220.57	-$198.97M	-$4.01	N/A
Arbutus Biopharma	$14.08M	73.28	-$33.50M	$0.79	6.60

uniQure has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

uniQure presently has a consensus target price of $65.00, suggesting a potential upside of 26.97%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential downside of 4.12%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has a net margin of 84.22% compared to uniQure's net margin of -1,350.73%. Arbutus Biopharma's return on equity of 90.98% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Arbutus Biopharma	84.22%	90.98%	82.34%

78.8% of uniQure shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arbutus Biopharma had 11 more articles in the media than uniQure. MarketBeat recorded 13 mentions for Arbutus Biopharma and 2 mentions for uniQure. uniQure's average media sentiment score of 1.54 beat Arbutus Biopharma's score of 0.83 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Arbutus Biopharma	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

uniQure and Arbutus Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, Arbutus Biopharma had 2 more articles in the media than Veracyte. MarketBeat recorded 13 mentions for Arbutus Biopharma and 11 mentions for Veracyte. Veracyte's average media sentiment score of 1.40 beat Arbutus Biopharma's score of 0.83 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Veracyte has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.80	$66.35M	$1.41	31.04
Arbutus Biopharma	$14.08M	73.28	-$33.50M	$0.79	6.60

Veracyte presently has a consensus target price of $54.33, suggesting a potential upside of 24.13%. Arbutus Biopharma has a consensus target price of $5.00, suggesting a potential downside of 4.12%. Given Veracyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Veracyte is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

43.8% of Arbutus Biopharma shares are held by institutional investors. 1.6% of Veracyte shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arbutus Biopharma has a net margin of 84.22% compared to Veracyte's net margin of 20.37%. Arbutus Biopharma's return on equity of 90.98% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Arbutus Biopharma	84.22%	90.98%	82.34%

Veracyte has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Summary

Veracyte beats Arbutus Biopharma on 10 of the 17 factors compared between the two stocks.

How does Arbutus Biopharma compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Arbutus Biopharma (NASDAQ:ABUS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Arbutus Biopharma has a net margin of 84.22% compared to Celldex Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Arbutus Biopharma	84.22%	90.98%	82.34%

Arbutus Biopharma has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	2,103.48	-$258.76M	-$4.35	N/A
Arbutus Biopharma	$14.08M	73.28	-$33.50M	$0.79	6.60

Celldex Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Celldex Therapeutics presently has a consensus price target of $56.08, suggesting a potential upside of 35.96%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential downside of 4.12%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Celldex Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Arbutus Biopharma had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Arbutus Biopharma and 3 mentions for Celldex Therapeutics. Arbutus Biopharma's average media sentiment score of 0.83 beat Celldex Therapeutics' score of 0.67 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

43.8% of Arbutus Biopharma shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Arbutus Biopharma beats Celldex Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.03B	$4.04B	$7.32B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	6.58	11.72	271.20	24.17
Price / Sales	73.28	1,431.37	696.57	128.56
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	13.04	17.52	11.33	6.51
Net Income	-$33.50M	-$22.72M	$3.46B	$347.63M
7 Day Performance	7.75%	4.50%	3.12%	1.53%
1 Month Performance	19.06%	11.99%	8.67%	5.17%
1 Year Performance	49.00%	60.24%	27.37%	17.69%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	1.2769 of 5 stars	$5.22 +0.3%	$5.00 -4.1%	+44.8%	$1.03B	$14.08M	6.58	90	News Coverage Buyback Announcement High Trading Volume
ABCL AbCellera Biologics	1.5997 of 5 stars	$11.20 -1.6%	$12.83 +14.6%	+141.7%	$3.49B	$75.13M	N/A	500	Positive News Gap Up
GMTX Gemini Therapeutics	N/A	$78.84 -1.5%	N/A	+32.2%	$3.42B	N/A	N/A	30
QURE uniQure	3.2736 of 5 stars	$47.97 -1.3%	$65.00 +35.5%	+202.3%	$3.37B	$16.10M	N/A	500	Positive News
VCYT Veracyte	4.3678 of 5 stars	$42.08 +2.0%	$54.33 +29.1%	+33.8%	$3.32B	$561.90M	29.84	790	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. ABCL, GMTX, QURE, VCYT, and CLDX

How does Arbutus Biopharma compare to AbCellera Biologics?

Summary

How does Arbutus Biopharma compare to Gemini Therapeutics?

Summary

How does Arbutus Biopharma compare to uniQure?

Summary

How does Arbutus Biopharma compare to Veracyte?

Summary

How does Arbutus Biopharma compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. ABCL, GMTX, QURE, VCYT, and CLDX

How does Arbutus Biopharma compare to AbCellera Biologics?

Is ABUS or ABCL more profitable?

Do analysts rate ABUS or ABCL?

Do institutionals & insiders have more ownership in ABUS or ABCL?

Which has better earnings and valuation, ABUS or ABCL?

Does the media favor ABUS or ABCL?

Which has more volatility & risk, ABUS or ABCL?

Summary

How does Arbutus Biopharma compare to Gemini Therapeutics?

Which has better earnings & valuation, GMTX or ABUS?

Is GMTX or ABUS more profitable?

Do insiders and institutionals believe in GMTX or ABUS?

Does the media prefer GMTX or ABUS?

Which has more risk & volatility, GMTX or ABUS?

Do analysts rate GMTX or ABUS?

Summary

How does Arbutus Biopharma compare to uniQure?

Which has better valuation and earnings, QURE or ABUS?

Which has more risk and volatility, QURE or ABUS?

Do analysts rate QURE or ABUS?

Is QURE or ABUS more profitable?

Do institutionals and insiders have more ownership in QURE or ABUS?

Does the media refer more to QURE or ABUS?

Summary

How does Arbutus Biopharma compare to Veracyte?

Does the media refer more to VCYT or ABUS?

Which has preferable valuation & earnings, VCYT or ABUS?

Do analysts recommend VCYT or ABUS?

Do insiders & institutionals have more ownership in VCYT or ABUS?

Is VCYT or ABUS more profitable?

Which has more volatility & risk, VCYT or ABUS?

Summary

How does Arbutus Biopharma compare to Celldex Therapeutics?

Is CLDX or ABUS more profitable?

Which has stronger earnings & valuation, CLDX or ABUS?

Which has more volatility & risk, CLDX or ABUS?

Do analysts prefer CLDX or ABUS?

Does the media favor CLDX or ABUS?

Do insiders and institutionals have more ownership in CLDX or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools